RxDoctor Payments Data

Alison Gimbel

Pulmonary Disease · Pittsburgh, PANPI 1043244593

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $12,399 of the $16,746 with a category attached, or 74.0%. AstraZeneca accounts for 87.1% of it on its own, with 2 other manufacturers making up the rest.

$16,746in general payments, 2019–2025

Across 12 payments — averaging $1395.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • Astrazeneca UK Limited$2K
  • GSK$29
$287,196in research payments, 2019–2025

Across 5 payments — averaging $57,439 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$277K
  • Gilead$10K

What the payments were for

  • Consulting fees$4,02824%
  • Travel & lodging$12,39974%
  • Food & beverage$3202%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$14,594
Astrazeneca UK Limited8$2,123
GSK1$29

How this compares

$16,746 in reported general payments places this provider in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,712
Medicare patients
18
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →